E
Passage Bio, Inc. PASG
$0.3117 -$0.0145-4.45% NASDAQ
Recommendation
Prev Close
$0.3262
Volume
83,817
Avg Vol (90D)
332,265
Market Cap
$20.27M
Dividend & Yield
--
52-Week Range
$0.30 - $1.64
P/E (TTM)
--
EPS (TTM)
-$1.08
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Sells $21,822.40 in Stock
4/27/2025 - Ticker Report
Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 77,090 Shares
4/18/2025 - Ticker Report
Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 77,090 Shares
4/18/2025 - MarketBeat
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know
3/7/2025 - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX), Black Diamond Therapeutics (BDTX) and Passage Bio (PASG)
3/7/2025 - TipRanks Financial Blog
Passage Bio (NASDAQ:PASG) Posts Earnings Results, Beats Estimates By $0.01 EPS
3/6/2025 - Ticker Report
Passage Bio price target lowered by $1 at Chardan, here's why
3/4/2025 - The Fly
Passage Bio reports FY24 EPS ($1.07) vs ($1.86) last year
3/4/2025 - TipRanks Financial Blog
Passage Bio reports FY24 EPS ($1.07) vs ($1.86) last year
3/4/2025 - The Fly
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent ...
3/4/2025 - GuruFocus
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
3/4/2025 - Globe Newswire
Passage Bio to Participate in Upcoming Investor Conferences
2/26/2025 - GuruFocus
Passage Bio to Participate in Upcoming Investor Conferences
2/26/2025 - Globe Newswire
Passage Bio will again trim workforce in latest cost-cutting move
2/16/2025 - Bizjournals.com - Health Care News
Orbimed Advisors Llc Sells 126,209 Shares of Passage Bio, Inc. (NASDAQ:PASG) Stock
1/15/2025 - MarketBeat
Analyzing Passage Bio (NASDAQ:PASG) & JATT Acquisition (NYSE:JATT)
1/15/2025 - Ticker Report
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc
1/15/2025 - GuruFocus
Passage Bio (NASDAQ:PASG) Announces Restructuring Plan and Financial Update
1/14/2025 - Ticker Report
Passage Bio, Inc. (NASDAQ:PASG) Shares Purchased by Geode Capital Management LLC
1/13/2025 - Ticker Report
igm y mabs passage bio and more telegraph staff cuts amid pipeline and business structure
1/10/2025 - FierceBiotech.com - Biotech
Passage Bio Restructures and Extends Cash Runway
1/10/2025 - TipRanks Financial Blog
Passage Bio announces data from upliFT-D study in FTD-GRN, provides update
1/10/2025 - The Fly
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
1/10/2025 - GuruFocus
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
1/10/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$62.09M
EBIT (TTM)
-$65.17M
Net Income (TTM)
-$64.77M
Balance Sheet
Total Assets (Q)
$102.41M
Total Debt (Q)
$25.48M
Total Liabilities (Q)
$41.15M
Book Value Per Share (Q)
$0.9871
Cash Flow
Cash from Operations (TTM)
-$47.96M
Cash from Investing (TTM)
$54.95M
Cash from Financing (TTM)
$8.87M
Net Change in Cash (TTM)
$15.86M
Filings
Filing Date
Tuesday, March 4, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.42
7-Day Total Return
-5.55%
30-Day Total Return
-19.46%
60-Day Total Return
-46.63%
90-Day Total Return
-56.83%
Year to Date Total Return
-62.45%
1-Year Total Return
-76.02%
2-Year Total Return
-69.14%
3-Year Total Return
-84.02%
5-Year Total Return
-98.30%
52-week Low
Apr 07, 2025 - $0.30
52-week High
May 08, 2024 - $1.64
Valuation
Market Cap
$20.27M - Nano Cap
Enterprise Value
-$31.01M
Price/Sales (TTM)
--
Price/Book (Q)
0.33
Dividends and Shares
Shares Outstanding
61.86M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.passagebio.com
Phone Number
(267) 866-0311
Address
One Commerce Square
2005 Market Street - 39th Floor
Philadelphia, PA 19103
Country
United States
Year Founded
2017
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1... more
NASDAQ 04/29/2025 4:00PM Eastern Quotes delayed